Hong Kong stock biotechnology stocks are rising across the board: GENOR-B is up over 10%, JACOBIO-B is up over 7%.

On April 1st, Gelonghui reports that IMMUNEONCO-B surged nearly 20%, AKESO rose over 12%, GENOR-B increased more than 10%, and BOAN BIO escalated over 9%. Both ASCENTAGE-B and JACOBIO-B grew over 7%, while ASCENTAGE-B rose over 6%. INNOCARE, OCUMENSION-B, ASCLETIS-B, CSTONE PHARMA-B, SKB BIO-B, and Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. all increased by more than 5%.

Gelonghui FinanceApr 1 15:24

GENOR-B (06998) announced its 2024 annual results, with a net loss of 52.974 million yuan, a year-on-year reduction of 92.2%.

GENOR-B (06998) released its 2024 annual performance, with a revenue of 0.206 billion yuan (Renminbi, the same below), ...

Zhitong FinanceMar 30 18:10

GENOR-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2024

HKEXMar 30 18:05 · Announcements

GENOR-B (06998.HK) plans to hold a Board of Directors meeting on March 28 to approve the annual performance.

Gelonghui, on March 18, announced that GENOR-B (06998.HK) will hold a Board of Directors meeting on March 28, 2025 (Friday), to consider and approve the full year performance of the company and its subsidiaries for the year ending December 31, 2024, and its release.

Gelonghui FinanceMar 18 17:19

GENOR-B: DATE OF BOARD MEETING

HKEXMar 18 17:00 · Announcements

All the way up! The Innovative Drugs Sector in Hong Kong stocks surged collectively, with multiple stocks doubling this year. Who is reshaping the valuation?

The rise in the Hong Kong stock market's Innovative Drugs Sector continues. Market analysts point out that this wave of Innovative Drugs momentum benefits from a combination of factors including market sentiment, policy, and the realization of the companies' own commercial value.

Securities TimesMar 13 09:50